Next 10 |
home / stock / snti / snti articles
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia ("AML"), on track for the second quarter ...
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of investors in the following Special P...
Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf...
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday The Dow traded up 0.19% to 34,1...
U.S. stocks traded mixed this morning, with the Dow Jones falling around 50 points on Tuesday Following the market opening Tuesday, the Dow traded ...
Senti Biosciences Inc (NASDAQ: SNTI) announced a new strategic collaboration with Celest Therapeutics (Shanghai) Co Ltd, a China-based bi...
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic col...
– Two poster presentations highlighting new preclinical data with BlueRock Therapeutics – – Two poster presentations showcasing Senti Bio...
News, Short Squeeze, Breakout and More Instantly...
Senti Biosciences Inc. Company Name:
SNTI Stock Symbol:
NASDAQ Market:
– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Sen...
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia ("AML"), on track for the second quarter ...
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ( ...